Streetbeat News

Revenues

KPTI

Karyopharm Therapeutics Inc. anticipates its preliminary unaudited full year 2023 total revenue to be around $146 million, which is below the estimated $150.03 million. The company also expects its preliminary Q4 revenue to be $33.6 million, falling short of the estimated $37.64 million.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:59 pm

BREA

Brera Holdings PLC reported a six-month earnings per share (EPS) of €(0.14) compared to €(0.03) year-over-year (YoY), and a revenue decline to €79.031 million from €131.521 million YoY.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:57 pm

CERS

Cerus Corporation reported preliminary Q4 product revenues of $46.8M and forecasts FY23 product revenues of $156.4M. The company also anticipates 2024 product revenues to be between $172M and $175M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:56 pm

CRMD

CorMedix Inc. (NASDAQ:CRMD) has announced updates on the commercial launch of DefenCath, including a submitted HCPCS application for a J-Code to CMS, ongoing discussions for Medicare Part B reimbursement, and interest from health systems. The inpatient launch is expected by April 15, 2024, and outpatient availability is anticipated no sooner than July 1, 2024, pending CMS decisions. CorMedix may set an initial list price for DefenCath before CMS's final determination, with plans to adjust it based on the outcome. The company has sufficient funds for the launch and is expanding its staff in preparation.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:54 pm

IDAI

Trust Stamp (NASDAQ:IDAI) reported that 45 customers have started or completed integration with its Orchestration Layer by the end of 2023. This marks a significant increase from the 22 customers reported in January 2023. The Orchestration Platform is designed to streamline the delivery and implementation of the company's AI-powered technologies. Trust Stamp's President, Andrew Gowasack, expressed satisfaction with the 2023 progress and aims to further grow the user base and support existing customers. The platform targets US financial institutions but is also applicable in various sectors globally.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:52 pm

SRFM

Surf Air Mobility Inc. (NYSE:SRFM) has entered into an agreement with Williamsport, Pennsylvania to launch a subsidized commuter air service between Williamsport Regional Airport and Washington Dulles International Airport, starting May 2024. The service will be operated by Southern Airways Express, a subsidiary of Surf Air Mobility, and aims to provide easier and more affordable connections for the local community. The agreement follows a similar one with Purdue University and is part of Surf Air's strategy to enhance regional connectivity through partnerships.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:51 pm

DENN

Denny's Corporation reported a 1.3% increase in domestic system-wide same-restaurant sales for Q4 and a 3.5% increase for the full year.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:47 pm

STIM

Neuronetics, Inc. reported preliminary unaudited total revenue for FY23 over $71M, slightly below the high end of its guidance range of $70M-$72M. The company saw a record Q4, with over 20% utilization growth among local consumable customers and increased usage by Greenbrook. The company achieved positive cash flow of over $1M in Q4. Looking ahead to 2024, Neuronetics is set to expand the Better Me Guarantee Provider pilot program, with 100 customer sites starting in January and over 275 eligible later in the year.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:46 pm

NWL

Newell Brands (NWL) announced an organizational realignment aimed at strengthening its commercial capabilities and reducing overhead costs. The plan includes a 7% reduction in office roles by the end of 2024, with expected annualized pre-tax savings of $65M-$90M, net of reinvestment. The realignment supports the 'Where to Play / How to Win' strategy introduced in June 2023. Restructuring charges are estimated to be $75M-$90M, with savings of $55M-$70M expected in 2024. Additional details will be shared in an SEC Form 8-K and during the Q4/full-year 2023 earnings call on February 9, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:45 pm

ITOS

iTeos Therapeutics has outlined its strategic priorities for 2024, including anticipated clinical data readouts for its TIGIT program and adenosine portfolio. The company expects its cash balance of $644.9M as of September 30, 2023, to fund operations through 2026. Key milestones include Phase 2 trials for belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC, and Phase 2 and Phase 1 trials for inupadenant and EOS-984, respectively.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:45 pm